New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation
Open Access
- 17 November 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (22) , e016836
Abstract
Background: Bleeding is frequent in patients with atrial fibrillation (AF) treated with oral anticoagulant therapy, and may be the first manifestation of underlying cancer. We sought to investigate to what extent bleeding represents the unmasking of an occult cancer in patients with AF treated with oral anticoagulants. Methods and Results: Using data from CardioCHUVI‐AF (Retrospective Observational Registry of Patients With Atrial Fibrillation From Vigo's Health Area), 8753 patients with AF aged ≥75 years with a diagnosis of AF between 2014 and 2017 were analyzed. Of them, 2171 (24.8%) experienced any clinically relevant bleeding, and 479 (5.5%) were diagnosed with cancer during a follow‐up of 3 years. Among 2171 patients who experienced bleeding, 198 (9.1%) were subsequently diagnosed with cancer. Patients with bleeding have a 3‐fold higher hazard of being subsequently diagnosed with new cancer compared with those without bleeding (4.7 versus 1.4 per 100 patient‐years; adjusted hazard ratio [HR], 3.2 [95% CI, 2.6–3.9]). Gastrointestinal bleeding was associated with a 13‐fold higher hazard of new gastrointestinal cancer diagnosis (HR, 13.4; 95% CI, 9.1–19.8); genitourinary bleeding was associated with an 18‐fold higher hazard of new genitourinary cancer diagnosis (HR, 18.1; 95% CI, 12.5–26.2); and bronchopulmonary bleeding was associated with a 15‐fold higher hazard of new bronchopulmonary cancer diagnosis (HR, 15.8; 95% CI, 6.0–41.3). For other bleeding (nongastrointestinal, nongenitourinary, nonbronchopulmonary), the HR for cancer was 2.3 (95% CI, 1.5–3.6). Conclusions: In patients with AF treated with oral anticoagulant therapy, any gastrointestinal, genitourinary, or bronchopulmonary bleeding was associated with higher rates of new cancer diagnosis. These bleeding events should prompt investigation for cancers at those sites.Keywords
This publication has 19 references indexed in Scilit:
- Association of Atrial Fibrillation and CancerJAMA Cardiology, 2016
- Risk of Malignant Cancer Among Women With New-Onset Atrial FibrillationJAMA Cardiology, 2016
- Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of PhysiciansAnnals of Internal Medicine, 2016
- Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or WarfarinJACC, 2015
- Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2015
- The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillationEuropean Heart Journal, 2015
- Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?Annals of Medicine, 2014
- Atrial Fibrillation as a Marker of Occult CancerPLOS ONE, 2014
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Hemoptysis: Etiology, Evaluation, and Outcome in a Tertiary Referral HospitalChest, 1997